Penny Stock Swing Trade Alert for 3.19.2020 $CODX

What Is a Penny Stock: A penny stock refers to a small company’s stock that typically trades for less than $5 per share. Although some penny stocks trade on large exchanges such as the New York Stock Exchange (NYSE), most penny stocks trade via over the counter (OTC) transactions. Transactions take place through the electronic OTC Bulletin Board (OTCBB) or through the privately-owned Pink Sheets. There is no trading floor for OTC transactions, and the quotations are also all done electronically.

The desire to make a quick killing in the stock market draws many inexperienced investors to trade in penny stocks. Unfortunately, this also means many people lose their money in the blink of an eye.

Why would anyone take on this type of risk? As the saying goes, “the higher the risk, the higher the potential returns.” If invested in the right companies, penny stocks can provide enormous returns. So if you’re comfortable with the risk versus return trade-off, and understand that you could lose your money, penny stocks could play a role in your portfolio.

Best Penny Stocks to Trade is a group whose objective is to help traders find the best swing trades for success.

Our alerts/signals come from an algorithmic system that we created for penny stock/ OTC swinging.

Before we release our system to the public, we’re going to spend the next 6 months posting alerts. You will be able to look back at these alerts to see how successful they are.

Penny Stock Swing Trade Alert for 3.18.2020 —> CODX

Co-Diagnostics Inc (NASDAQ: CODXshares were rallying Tuesday following an update from the company regarding its COVID-19 test.

The molecular diagnostic company said a revised FDA policy on COVID-19 diagnostic testing that was announced Monday will allow the company to “aggressively expand” its presence in the U.S.

FDA Eases Testing Rules

An update to the FDA policy, originally issued Feb. 29, aims to create more rapid testing capacity in the U.S.

The new measures, among other things, call for states to take responsibility for tests used by labs in the respective states.

As opposed to the earlier rule allowing only high-complexity testing consistent with requirements under the Clinical Laboratory Improvement Amendments to carry out testing, the FDA now said it does not object to commercial manufacturers distributing and labs using new commercially developed tests prior to the agency granting emergency use authorization, or EUA, under certain circumstances.

Be the first to comment

Leave a Reply

Your email address will not be published.